Biofilm production and antifungal susceptibility patterns of Candida species;Candida türlerinin biyofilm üretimi ve antifungal duyarlilik paternleri

Mikrobiyoloji Bulteni

Volumn 38, Issue 1-2, 2004, Pages 91-98

  Yücesoy, Mine ^a   Karaman, Meral ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Amphotericin B; Antifungal susceptibility; Biofilm; Candida spp; Fluconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOFILM; CANDIDA; DOSE RESPONSE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIOLOGICAL EXAMINATION; PATHOGENICITY; REPRODUCIBILITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; VIRULENCE FACTORS;

EID: 28744436662     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Leonhardt A, Renvert S, Dahlen G: Microbial findings at failing implants. Clin Oral Implants Res 1999, 10: 339-345.
2. Ballie GS, Douglas LJ: Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1999, 42: 1900-1905.
3. Bachmann SP, Vande Walle K, Ramage G, et al: In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002, 46: 3591-3596.
4. Douglas LJ: Candida biofilms and their role in infection. Trends in Microbiology 2003, 11: 30-36.
5. Calderone R, Gow NAR: Host recognition by Candida species, p. 67-86. In: Calderone RA (ed), Candida and Candidiasis. 2002, 18t ed. Amer Soc Microb Press, Washington DC.
6. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD: Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994, 32: 452-456.
7. Pfaller M, Davenport D, Bale M, Barrett M, Koontz F, Massarani R: Development of the quantitative micro-test for slime production by coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 1988, 7: 30-33.
8. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard, NCCLS document M27-A2. 2002, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
9. Crump JA, Collignon PJ: Intravascular catheter-associated infections. Eur J Clin Microbiol Infect Dis 2000, 19: 1-8.
10. Ramage G, Wickes BL, Lopez-Ribot JL: Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 2001, 20: 42-44.
11. Potera C: Forging a link between biofilms and disease. Science 1999, 283: 1837-1838.
12. Jansen B, Schumacher-Perdreau F, Peters G, et al: New aspects in the pathogenesis and prevention of polymer-associated, foreign-body infections caused by coagulase-negative staphylococci. J Invest Surg 1989, 2: 361-380.
13. Yücesoy M, Karaman M, Yuluǧ N: Candida türlerinde "slime" üretiminin incelenmesi. Dokuz Eylül Üniversitesi Tιp Fak Derg 2000, 14: 65-70.
14. Orhon H, Özbakkaloǧlu B, Sürücüoǧlu S, Tünger Ö, Sivrel A: İnfeksiyon etkeni olan Candida albicans suşlarιnda slime üretimi ve antifungal ajanlara duyarlιlιklarι. Tropikal Hastalιklar Kongresi, 15-20 Haziran 1998, Van.
15. Shin JH, Kee SJ, Shin MG, et al: Biofilm production by isolates Candida species recovered from non-neutropenic patients: Comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002, 40: 1244-1248.
16. Karagöz S, Koç AN, Çetinkaya F: Hastane infeksiyonu etkeni olarak düşünülen maya izolatlarιnιn slime ve proteinaz aktiviteleri. 1. Ulusal Mantar Hastalιklan ve Klinik Mikoloji Kongresi, 4-6 Mayιs 1999. Bildiri ve Özet Kitabι, s. 277.
17. Hawser SP, Douglas LJ: Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immum 1994, 62: 915-921.
18. Girmenia C, Martino P, De Bernardis F, et al: Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: Clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996, 23: 506-514.
19. Hawser SP, Douglas LJ: Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995, 39: 2128-2131.
20. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL: Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001, 45: 2475-2479.
21. Douglas LJ: Medical importance of biofilms in Candida infections. Rev Iberoam Micol 2002, 19: 139-143.
22. Kumamoto CA: Candida biofilms. Current Opinion in Microbiology 2002, 5: 608-611.
23. Davenport DS, Massanari RM, Pfaller MA, Bale MJ, Streed SA, Hierhofzer WJ. Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis 1986, 153: 332-339.
24. Diaz-Mitoma F, Harding GKM, Hoban DJ. Roberts RS, Low DE: Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. J Infect Dis 1987, 156: 555-560.